Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152).

Sunagar, Raju; Prasad, Sai D; Ella, Raches; Vadrevu, Krishna Mohan

Sunagar, Raju; Prasad, Sai D; Ella, Raches; Vadrevu, Krishna Mohan.

Afiliação

Sunagar R; Bharat Biotech International Ltd, Hyderabad, India.
Prasad SD; Bharat Biotech International Ltd, Hyderabad, India.
Ella R; Bharat Biotech International Ltd, Hyderabad, India.
Vadrevu KM; Bharat Biotech International Ltd, Hyderabad, India.

Front Immunol ; 13: 1063679, 2022.

Article em En | MEDLINE | ID: mdl-36569867

Assuntos

Adenovirus dos Símios; COVID-19; Cricetinae; Humanos; Animais; Camundongos; Coelhos; Ratos; Idoso; Vacinas contra COVID-19/efeitos adversos; COVID-19/prevenção & controle; SARS-CoV-2; Anticorpos Neutralizantes

Palavras-chave

BBV154; COVID-19 vaccine; ChAd vaccine; SARS-CoV-2; heterologous; iNCOVACC; intranasal vaccine; mucosal vaccine

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Adenovirus dos Símios / COVID-19 Limite: Aged / Animals / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google